Special Populations Across the Lifespan

Pediatric and Adolescent Populations

Children and adolescents with diabetes require developmentally tailored, individualized glycemic targets rather than a single fixed number applied to every age. Management must weigh the benefits of tight control against the risks of hypoglycemia on a still-developing brain and the practical realities of school, sports, and a growing child's changing insulin sensitivity. Most youth with type 1 diabetes work toward an A1C goal in the same range as adults (around <7%), individualized upward for very young children, those with hypoglycemia unawareness, or limited access to frequent monitoring, and downward when tighter control can be achieved safely. Targets are set collaboratively with the family and reassessed as the child matures.

• Family involvement is central at every age. Diabetes management responsibility should shift from parent/caregiver to child gradually and only as developmentally appropriate — premature transfer of full self-management to a young adolescent is a well-documented cause of deteriorating control, since executive function and risk judgment are still maturing. Diabetes education should always include the family, not only the child, and should be revisited at each developmental stage rather than delivered once at diagnosis.
• School is a major daily setting for care. A Diabetes Medical Management Plan (DMMP), developed with the family and provider, translates into a Section 504 Plan or Individualized Health Care Plan (IHCP) that legally obligates the school to provide trained personnel who can recognize and treat hypoglycemia, administer glucagon, and allow the student to self-carry supplies (glucose meter, fast-acting carbohydrate, insulin) and self-treat as appropriate for age and competency. CDCES professionals often help families and school nurses translate a DMMP into a workable daily routine.
• Growth and technology considerations. Insulin needs rise during pubertal growth spurts due to insulin-resistance from growth hormone and sex hormones, and regimens should be reviewed at each growth stage rather than left static. Continuous glucose monitors and insulin pumps are widely used in pediatrics and can reduce the burden of frequent fingersticks and injections, but device fatigue and body-image concerns about wearing visible devices are common adolescent barriers worth screening for directly.
• Disordered eating screening deserves particular attention in adolescents with type 1 diabetes, including deliberate insulin omission for weight control (sometimes called "diabulimia"), which carries serious short- and long-term complication risk and is more common in this population than in peers without diabetes.

Older Adults

Older adults with diabetes are a highly heterogeneous population, and the ADA stratifies glycemic goals by overall health status rather than age alone, because chronological age poorly predicts life expectancy, hypoglycemia risk, or the ability to safely tolerate tight control.

Hypoglycemia avoidance becomes the overriding safety priority as health status declines: cognitive impairment can mask early warning symptoms, polypharmacy increases interaction risk, age-related renal decline prolongs clearance of insulin and sulfonylureas, and hypoglycemic events raise fall and fracture risk. Deprescribing is an active clinical strategy, not neglect — simplifying multidrug regimens, discontinuing agents with high hypoglycemia risk (sulfonylureas, sometimes insulin) once goals shift toward comfort and safety, and revisiting the appropriateness of tight blood-pressure or lipid targets through shared decision-making with the person and family, particularly when life expectancy is limited. Functional and cognitive screening (for example, a brief cognitive test and an assessment of instrumental activities of daily living) at routine visits helps place an individual correctly on the health-status framework rather than relying on age or diagnosis list alone. CGM use is increasingly recommended in older adults on insulin specifically because it can detect asymptomatic and nocturnal hypoglycemia that fingerstick checks would miss, which is especially valuable once hypoglycemia awareness has declined.

Transplant Populations

Two distinct transplant scenarios appear on the exam:

• Pancreas and islet-cell transplantation are treatment options for selected people with type 1 diabetes, most often performed as a simultaneous pancreas-kidney (SPK) transplant in someone who also needs a kidney transplant for diabetic nephropathy; a pancreas-transplant-alone is occasionally used for recurrent severe hypoglycemia or hypoglycemia unawareness in type 1 diabetes without kidney failure. A successful transplant can restore insulin independence, but it requires lifelong immunosuppression and careful patient selection.
• Post-transplant diabetes mellitus (PTDM), formerly called new-onset diabetes after transplant (NODAT), develops in solid-organ transplant recipients — kidney, liver, heart, or lung — who did not have diabetes beforehand. It is driven primarily by the immunosuppressant regimen: corticosteroids and calcineurin inhibitors (tacrolimus more than cyclosporine) impair both insulin secretion and insulin sensitivity. People with PTDM need glucose monitoring integrated into their transplant follow-up, careful attention to drug interactions between diabetes medications and immunosuppressants, and reinforced infection-prevention education, since immunosuppression plus hyperglycemia compounds infection risk. Metformin is often avoided early after transplant because of fluctuating renal function, so insulin is frequently the initial agent of choice before a longer-term regimen is established once graft function stabilizes.